Início › Leucemia Linfocítica Crônica › Wisconsin
Ensaios clínicos de Leucemia Linfocítica Crônica em Wisconsin
19 estudos para Leucemia Linfocítica Crônica estão buscando participantes em locais em Wisconsin.
Cidades em Wisconsin
Texto oficial do estudo (Inglês)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Duluth Clinic Ashland, Ashland
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- e mais 7
RecrutandoFase 3
Idades 65 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- ThedaCare Regional Cancer Center, Appleton
- ThedaCare Regional Medical Center - Appleton, Appleton
- e mais 50
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- Duluth Clinic Ashland, Ashland
- Marshfield Medical Center-EC Cancer Center, Eau Claire
- e mais 14
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT04269902A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Medical College of Wisconsin, Milwaukee
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Gunderson Health System, La Crosse
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical ( Site 0048), Madison
- University Hospital and UW Health Clinics ( Site 0006), Madison
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Medical College of Wisconsin, Milwaukee
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- The Medical College of Wisconsin, Milwaukee
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07221500Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Medical College of Wisconsin, Milwaukee
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT03666000A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Medical College of Wisconsin, Milwaukee
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de jul. de 2026 · NCT05131022Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- Medical College of Wisconsin, Milwaukee
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 13 de mar. de 2026 · NCT07218510A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Medical College of Wisconsin, Milwaukee
RecrutandoFase 4
Idades 18 e acima · Todos os sexos · Atualizado em 2 de mar. de 2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Medical College of Wisconsin, Milwaukee
RecrutandoFase 4
Idades 18 e acima · Todos os sexos · Atualizado em 2 de mar. de 2026 · NCT06876649CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
- Medical College of Wisconsin and Froedtert Hospital, Milwaukee
RecrutandoFase 1/2
Idades de 18 a 80 · Todos os sexos · Atualizado em 23 de fev. de 2026 · NCT04186520Study of SGR-1505 in Mature B-Cell Neoplasms
- Medical College of Wisconsin, Milwaukee
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT05544019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- The Medical College of Wisconsin, Milwaukee
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 10 de dez. de 2025 · NCT05602363In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
- University of Wisconsin, Madison
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades 18 e acima · Todos os sexos · Atualizado em 26 de nov. de 2025 · NCT04785989Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
RecrutandoEstudo observacional
Idades de 18 a 80 · Todos os sexos · Atualizado em 10 de nov. de 2025 · NCT03375619A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
- Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 24 de fev. de 2025 · NCT06788639Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.